FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E

EXPLORE DATA
VISUALIZATIONS

Explore key data on health and its determinants in India through interactive graphs.

Risk and burdens of Incident diabetes in long covid: a cohort study

21 Apr 2022
Emerging Pandemics

by Yan Xie, Ziyad Al-Aly 20 MIN

There is growing evidence that, after the acute phase of SARS-CoV-2 infection, people with COVID-19 may experience a wide range of post-acute sequelae, known as long COVID, that include pulmonary and extrapulmonary organ system manifestations, including diabetes outcomes. However, the risks and burdens of diabetes in the post-acute phase of the disease have yet to be fully defined. This study aims to fill a knowledge gap by investigating the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. The findings suggest that COVID-19 survivors had increased risks and burdens of incident diabetes and antihyperglycemic use after the first 30 days of infection. The risks and burdens were significant among those who were not hospitalized and increased in a graded fashion depending on the acute phase of the disease's care setting. In comparison to a historical control group, the risks and burdens were also consistent. All in all, the findings suggest that, after the acute phase of COVID-19, survivors are at an increased risk of developing incident diabetes and using antihyperglycemic medications; thus, diabetes should be considered as a component of the multifaceted long COVID. Post-acute care strategies for people with COVID-19 should include diabetes screening and management.

Related File :

7952791233.pdf

Categories

COVID-19
KEY ORGANIZATIONS
Connect with Us

FOLLOW US

Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2025 Swasti Health Catalyst